Blood cancer patients get extended access to promising drug

NCT ID NCT06465433

Recruiting now Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated Apr 30, 2026 · Updated 19 times

Summary

This study offers ongoing treatment with tafasitamab for people with blood cancers who are already benefiting from the drug in an earlier study. It aims to keep providing the medicine while monitoring for side effects. About 25 participants will join this extension study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinica Universitad de Navarra
COMPLETED

Pamplona, 31008, Spain
Gazi University Hospital Gazi University Faculty of Medicine
RECRUITING

Ankara, 06500, Turkey (Türkiye)
Hospital S.M. Terni University of Perugia
COMPLETED

Terni, 05100, Italy
Petz Aladar County Teaching Hospital
RECRUITING

Győr, 09023, Hungary
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea

Conditions

Explore the condition pages connected to this study.

HEMATOLOGIC MALIGNANCIES